Atopic Dermatitis Market Size in the 7MM was ~USD 16,000 Million in 2022 | DelveInsight

Atopic Dermatitis Market Size in the 7MM was ~USD 16,000 Million in 2022 | DelveInsight

DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, Japan.

 

Key Takeaways from the Atopic Dermatitis Market Research Report

  • The total Atopic Dermatitis prevalent cases in the United States were around 32,573,900 cases in 2022.
  • Approximately 60–70% of Atopic Dermatitis diagnosed cases are mild, whereas ~30% are moderate-to-severe.
  • The increase in Atopic Dermatitis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
  • As per DelveInsight analysis, the Atopic Dermatitis Market is anticipated to witness growth at a considerable CAGR.
  • The leading Atopic Dermatitis Companies working in the market include Sanofi, Regeneron Pharmaceuticals, Pfizer, Japan Tobacco and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, Kymab, Arcutis Biotherapeutics, Qurient, Cara Therapeutics, Vanda Pharmaceuticals, and others.
  • Promising Atopic Dermatitis Pipeline Therapies in the various stages of development include Baricitinib, si-544, Lebrikizumab, MEDI9929, Dupilumab, Midazolam, Omeprazole, Emollient, and others.
  • April 2024: Suzhou Zelgen Biopharmaceuticals Co.,Ltd- A Phase I/II Study Of The Efficacy,Safety and PharmacokineticsOf Jaktinib Hydrochloride Cream In Subjects With Mild To Moderate Atopic Dermatitis. This study includes a dose escalation part and a dose extension part.
  • April 2024: Pfizer- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-07275315 AND PF-07264660 IN ADULT PARTICIPANTS WITH MODERATE-SEVERE ATOPIC DERMATITIS. The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.
  • April 2024: Eli Lilly and Company- An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab. The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.

 

Discover which therapies are expected to grab the Atopic Dermatitis Market Share @ Atopic Dermatitis Market Outlook

 

Atopic Dermatitis Overview

Atopic dermatitis, also known as eczema, is a chronic (long-lasting) skin condition characterized by dry, itchy, and inflamed skin. It is a type of atopic disorder, which includes other allergic conditions like hay fever and asthma, suggesting a genetic predisposition and a common underlying immune dysfunction.

 

Atopic Dermatitis Epidemiology Insights

The epidemiology section of Atopic Dermatitis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

  • Total Atopic Dermatitis Prevalent Cases
  • Total Atopic Dermatitis Prevalent Cases by age
  • Total Atopic Dermatitis Diagnosed Cases
  • Total Diagnosed Cases of Atopic Dermatitis by Severity
  • Total Diagnosed Cases of Atopic Dermatitis by Gender
  • Total Atopic Dermatitis Treated Cases

 

Download the report to understand which factors are driving Atopic Dermatitis Epidemiology trends @ Atopic Dermatitis Epidemiological Insights

 

Atopic Dermatitis Drugs Market

The Atopic Dermatitis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Atopic Dermatitis signaling in Atopic Dermatitis are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Atopic Dermatitis Treatment Market Landscape

The Atopic Dermatitis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Atopic Dermatitis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Atopic Dermatitis treatment guidelines, visit @ Atopic Dermatitis Treatment Market Landscape

 

Atopic Dermatitis Market Outlook

The report’s outlook on the Atopic Dermatitis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Atopic Dermatitis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Atopic Dermatitis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Atopic Dermatitis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Atopic Dermatitis Drugs Uptake

The drug chapter of the Atopic Dermatitis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Atopic Dermatitis.

 

Major Atopic Dermatitis Companies

Several Atopic Dermatitis Companies working in the market include Sanofi, Regeneron Pharmaceuticals, Pfizer, Japan Tobacco and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, Kymab, Arcutis Biotherapeutics, Qurient, Cara Therapeutics, Vanda Pharmaceuticals, and others.

 

Learn more about the FDA-approved drugs for Atopic Dermatitis @ Drugs for Atopic Dermatitis Treatment

 

Scope of the Atopic Dermatitis Market Research Report

  • Coverage- 7MM
  • Atopic Dermatitis Companies- Sanofi, Regeneron Pharmaceuticals, Pfizer, Japan Tobacco and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, Kymab, Arcutis Biotherapeutics, Qurient, Cara Therapeutics, Vanda Pharmaceuticals, and others.
  • Atopic Dermatitis Therapies- Baricitinib, si-544, Lebrikizumab, MEDI9929, Dupilumab, Midazolam, Omeprazole, Emollient, and others.
  • Atopic Dermatitis Market Dynamics: Atopic Dermatitis Market Drivers and Barriers

 

Discover more about Atopic Dermatitis Drugs in development @ Atopic Dermatitis Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Atopic Dermatitis (AD) Market Overview at a Glance

4. Epidemiology and Market Methodology

5. Executive Summary

6. Disease Background and Overview

7. Epidemiology and Patient Population

8. Patient Journey

9. Key Endpoints in Atopic Dermatitis Clinical Trials

10. Marketed Therapies

11. Emerging Therapies

12. Atopic Dermatitis (Atopic Dermatitis): The 7MM Analysis

13. Market Access and Reimbursement

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: